The estimated Net Worth of Barry Moze is at least $37.5 Million dollars as of 5 January 2022. Mr. Moze owns over 64,959 units of Horizon Therapeutics Plc stock worth over $16,356,432 and over the last 10 years he sold HZNP stock worth over $16,465,294. In addition, he makes $4,662,510 as Executive Vice President und Chief Administrative Officer at Horizon Therapeutics Plc.
Sign up
Mr. Moze HZNP stock SEC Form 4 insiders trading
Barry has made over 12 trades of the Horizon Therapeutics Plc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 64,959 units of HZNP stock worth $7,554,732 on 5 January 2022.
The largest trade he's ever made was selling 77,500 units of Horizon Therapeutics Plc stock on 5 November 2020 worth over $6,117,075. On average, Barry trades about 14,261 units every 57 days since 2014. As of 5 January 2022 he still owns at least 140,640 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Moze stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barry Moze biography
Barry J. Moze is Executive Vice President, Chief Administrative Officer of the Company. Prior to that, Mr. Moze was our executive vice president, chief operating officer from February 2016 to January 2017 and was our executive vice president, corporate development from May 2014 to January 2016. Prior to joining Horizon, Mr. Moze spent more than 28 years as a partner of Crystal Clear Communications, a consulting firm focused on the development and execution of corporate strategies. Prior to Crystal Clear, Mr. Moze was a founder and president of Review Services and Asset Management Group, a licensed investment advisory firm.
What is the salary of Barry Moze?
As the Executive Vice President und Chief Administrative Officer of Horizon Therapeutics Plc, the total compensation of Barry Moze at Horizon Therapeutics Plc is $4,662,510. There are 2 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.
How old is Barry Moze?
Barry Moze is 66, he's been the Executive Vice President und Chief Administrative Officer of Horizon Therapeutics Plc since 2017. There are 3 older and 20 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
What's Barry Moze's mailing address?
Barry's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC,, 70 SAINT STEPHEN?S GREEN, DUBLIN, L2, D02 E2X4.
Insiders trading at Horizon Therapeutics Plc
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... und Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
What does Horizon Therapeutics Plc do?
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
What does Horizon Therapeutics Plc's logo look like?
Complete history of Mr. Moze stock trades at Horizon Therapeutics Plc
Horizon Therapeutics Plc executives and stock owners
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Timothy Walbert,
Chairman of the Board, President, Chief Executive Officer -
Timothy P. Walbert,
Chairman, Pres & CEO -
Barry Moze,
Executive Vice President, Chief Administrative Officer -
Paul Hoelscher,
Chief Financial Officer, Executive Vice President -
Vikram Karnani,
Executive Vice President, President - International -
Paul W. Hoelscher,
Exec. VP & CFO -
Andy Pasternak,
Exec. VP & Chief Strategy Officer -
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
Exec. VP & Chief Medical Officer -
Michael Grey,
Lead Independent Director -
Jeffrey Himawan,
Independent Director -
H. Thomas Watkins,
Independent Director -
James Shannon,
Independent Director -
William Daniel,
Independent Director -
Pascale Witz,
Independent Director -
Susan Mahony,
Independent Director -
Irina Konstantinovsky,
Chief Human Resource Officer, Executive Vice President -
Daniel Camardo,
Executive Vice President, President - U.S. -
Jeffrey Kent,
Senior Vice President, Head of Medical Affairs and Outcomes Research -
Andy Pasternak,
Executive Vice President, Chief Business Officer -
Geoffrey Curtis,
Executive Vice President - Corporate Affairs, Chief Communications Officer -
Tina Ventura,
Senior Vice President, Investor Relations -
Michael DesJardin,
Executive Vice President - Technical Operations and Corporate Quality -
Brian Beeler,
Executive Vice President, General Counsel -
Aaron L. Cox,
Exec. VP of Fin. & CFO -
Jane Gonnerman,
Group VP of Corp. Devel., Chief of Staff & Office of the CEO -
Geoffrey M. Curtis,
Exec. VP of Corp. Affairs & Chief Communications Officer -
Sean M. Clayton J.D.,
Exec. VP & Gen. Counsel -
Timothy Ayers,
Chief Compliance Officer & VP -
Dr. Karin Rosen M.D., Ph.D.,
Exec. VP of R&D and Chief Scientific Officer -
Miles W. McHugh,
Chief Accounting Officer & Sr. VP -
Robert Carey,
EVP & Chief Business Officer -
Jeff Himawan,
Director -
Gino Santini,
Director -
Timothy J. Ackerman,
SVP, Commercial Operations -
Miles W Mc Hugh,
Sr VP & Princ. Acctg Officer -
George P Hampton,
See remarks -
Virinder Nohria,
Director -
Ronald Pauli,
Director -
Vaere Robert J De,
EVP & CFO -
Therapeutics Holdings Llc V...,
10% owner -
Todd N Smith,
SVP, Marketing & Alliance Mgmt -
David Happel,
EVP, Commercial Dev & Strategy -
Eric Mosbrooker,
SVP, Orphan Business Unit -
Shao Lee Lin,
EVP, Head of R&D and CSO -
Jeff Kent,
See remarks -
Jeffrey W Bird,
Director -
Michael Adatto,
Senior VP Sales & Managed Care -
Bio Ventures Ii Lp Quaker,
10% owner -
Venture Fund Vi Lp Atlas Ve...,
-
Peter Johann,
Director -
Jean Francois Formela,
Director -
Venture Fund Vi Lp Atlas Ve...,
-
Woodlands Health Ventures F...,
10% owner -
Louis C Bock,
Director -
Hubert Birner,
Director -
John B Thomas,
EVP, Corporate Strategy and IR -
David George Kelly,
EVP, Company Secretary -
John J Kody,
EVP, Chief Commercial Officer -
Balaji Venkataraman,
-
Aaron Cox,
EVP, Chief Financial Officer -
Jeffrey W Sherman,
EVP and Chief Medical Officer -
Karin Rosen,
EVP, R&D & CSO -
Elizabeth H.Z. Thompson,
EVP, Research & Development -
Sean M. Clayton,
EVP, General Counsel -
Jacopo Leonardi,
Pres., Global Commercial Ops -
Patrick Mc Ilvenny,
Chief Accounting Officer